Literature DB >> 29414633

The impact of rectal cancer tumor height on recurrence rates and metastatic location: A competing risk analysis of a national database.

Knut M Augestad1, Deborah S Keller2, Paul M Bakaki3, Johnie Rose4, Siran M Koroukian5, Tom Øresland6, Conor P Delaney7.   

Abstract

BACKGROUND: The impact of rectal cancer tumor height on local recurrence and metastatic spread is unknown. The objective was to evaluate the impact of rectal cancer tumor height from the anal verge on metastatic spread and local recurrence patterns.
METHODS: The Norwegian nationwide surgical quality registry was reviewed for curative rectal cancer resections from 1/1/1996-12/15/2006. Cancers were stratified into five height groups: 0-3 cm, >3-5 cm, >5-9 cm, >9-12 cm, 12 cm-HI. Competing risk and proportional hazards models assessed the relationship between tumor height and patterns of metastasis and survival.
RESULTS: 6859 patients were analyzed. After median follow-up of 52 months (IQR 20-96), 26.7% (n = 1835) experienced recurrence. With tumors >12 cm, the risk of liver metastases increased (crude HR 1.49, p = 0.03), while lung metastases decreased (crude HR 0.66, p = 0.03), and risk of death decreased (crude HR 0.81, p = 0.001) The cumulative incidence of pelvic recurrence were highest for the low tumors (p = 0.01). Median time to liver metastases was 14months (IQR 7-24), lung metastases 25months (IQR 13-39), pelvic recurrence 19months (IQR10-32), (p < 0.0001). Time to metastases in liver and lungs were significantly associated with tumor height (p < 0.001)
CONCLUSION: There are distinct differences in metastatic recurrence patterns and time to recurrence from different anatomic areas of the rectum. In crude analyses, tumor height impacted metastatic spread to the liver and lungs. However, when adjusting for treatment variables, the hazard of metastatic spread to the liver and lungs are limited. Nevertheless, time to metastases in liver and lungs is significantly impacted by tumor height. Venous drainage of the rectal cancer may be a significant contributor of rectal cancer metastatic spread, but further research is warranted.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Colorectal cancer; Local recurrence; Metastases

Mesh:

Year:  2018        PMID: 29414633     DOI: 10.1016/j.canep.2018.01.009

Source DB:  PubMed          Journal:  Cancer Epidemiol        ISSN: 1877-7821            Impact factor:   2.984


  8 in total

1.  Neoadjuvant chemoradiation improves oncologic outcomes in low and mid clinical T3N0 rectal cancers.

Authors:  Olga A Lavryk; Elena Manilich; Michael A Valente; Arshiya Miriam; Emre Gorgun; Matthew F Kalady; Sherief Shawki; Conor P Delaney; Scott R Steele
Journal:  Int J Colorectal Dis       Date:  2019-11-27       Impact factor: 2.571

2.  Oncological outcomes and stoma-free survival following TaTME, a prospective cohort study.

Authors:  S Hallam; F Ahmed; N Gouvas; S Pandey; D Nicol
Journal:  Tech Coloproctol       Date:  2021-02-19       Impact factor: 3.781

3.  Oncological and anorectal functional outcomes of robot-assisted intersphincteric resection in lower rectal cancer, particularly the extent of sphincter resection and sphincter saving.

Authors:  Jin Cheon Kim; Jong Lyul Lee; Joon Woo Bong; Ji Hyun Seo; Chan Wook Kim; Seong Ho Park; Jihoon Kim
Journal:  Surg Endosc       Date:  2019-07-22       Impact factor: 4.584

4.  Measurement of rectal tumor height from the anal verge on MRI: a comparison of internal versus external anal sphincter.

Authors:  David D B Bates; James L Fuqua; Junting Zheng; Marinela Capanu; Jennifer S Golia Pernicka; Sidra Javed-Tayyab; Viktoriya Paroder; Iva Petkovska; Marc J Gollub
Journal:  Abdom Radiol (NY)       Date:  2020-09-17

5.  The risk factors of local recurrence and distant metastasis on pT1/T2N0 mid-low rectal cancer after total mesorectal excision.

Authors:  I-Li Lai; Jeng-Fu You; Yih-Jong Chern; Wen-Sy Tsai; Jy-Ming Chiang; Pao-Shiu Hsieh; Hsin-Yuan Hung; Yu-Jen Hsu
Journal:  World J Surg Oncol       Date:  2021-04-13       Impact factor: 2.754

6.  Sex-related differences in primary metastatic site in rectal cancer; associated with hemodynamic factors?

Authors:  Sebastian Meltzer; Kine Mari Bakke; Karina Lund Rød; Anne Negård; Kjersti Flatmark; Arne Mide Solbakken; Annette Torgunrud Kristensen; Anniken Jørlo Fuglestad; Christian Kersten; Svein Dueland; Therese Seierstad; Knut Håkon Hole; Lars Gustav Lyckander; Finn Ole Larsen; Jakob Vasehus Schou; Dawn Patrick Brown; Hanna Abrahamsson; Kathrine Røe Redalen; Anne Hansen Ree
Journal:  Clin Transl Radiat Oncol       Date:  2019-12-02

7.  SEOM-GEMCAD-TTD clinical guidelines for localized rectal cancer (2021).

Authors:  Jaume Capdevila; Ma Auxiliadora Gómez; Mónica Guillot; David Páez; Carles Pericay; Maria José Safont; Noelia Tarazona; Ruth Vera; Joana Vidal; Javier Sastre
Journal:  Clin Transl Oncol       Date:  2022-03-18       Impact factor: 3.340

8.  The circulating soluble form of the CD40 costimulatory immune checkpoint receptor and liver metastasis risk in rectal cancer.

Authors:  Annette Torgunrud; Hanna Abrahamsson; Sebastian Meltzer; Arne Mide Solbakken; Kjersti Flatmark; Svein Dueland; Kine Mari Bakke; Paula Anna Bousquet; Anne Negård; Christin Johansen; Lars Gustav Lyckander; Finn Ole Larsen; Jakob Vasehus Schou; Kathrine Røe Redalen; Anne Hansen Ree
Journal:  Br J Cancer       Date:  2021-04-09       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.